PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems
2024-01-05
疫苗信使RNA寡核苷酸临床研究
SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- PassPort Technologies, Inc. (PPTI), led by President and CEO Tomoyuki Fujisawa in California, USA is pleased to announce the initiation of a collaborative research endeavor with Arcturus Therapeutics (ARCT). This research collaboration is focused on evaluating innovative mRNA formulations and transdermal delivery mechanisms for vaccines and therapeutics.
Continue Reading
The research collaboration will leverage ARCT's expertise in mRNA design and proprietary LUNAR® platform technologies, alongside PPTI's groundbreaking PassPort® transdermal drug delivery technology. PPTI will utilize its unique platform technology and extensive knowledge in transdermal biologics and oligonucleotides delivery. ARCT will supply select mRNA and LUNAR® formulations, which PPTI will subsequently adapt to the PassPort® system.
PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery
Post this
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive™, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiencyornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.
As a cutting-edge biotechnology entity, PPTI is committed to the swift development and patient delivery of exceptional pharmaceuticals through the PassPort system. The company aims to constantly develop technologies that serve not only the pharmaceutical industry but also broader life sciences sectors. PPTI's mission is to advance global health outcomes. Further details can be found at https://passport-tech.com.
About PassPort® Technology
The PassPort® System integrates microporation technology to painlessly form micropores in the skin seamlessly and a patch formulation technology that regulates drug delivery through these micropores. This innovative system now enables transdermal delivery of biologics and oligonucleotides, which were previously limited to injections and infusions.
■For inquiries regarding this matter, please contact:
E-mail: [email protected]
URL: https://passport-tech.com/
SOURCE PassPort Technologies, Inc.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。